CHANDRA ADHIKARI: Open Payments
NPI 1912754078 · LANSDOWNE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,853 in 128 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $1,307 · 2025 $2,853
Food & beverage: $2,853
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $650 |
| Madrigal Pharmaceuticals | 12 | $320 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $293 |
| GENZYME CORPORATION | 8 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $200 |
| Regeneron Healthcare Solutions, Inc. | 4 | $190 |
| PFIZER INC. | 9 | $176 |
| Janssen Biotech, Inc. | 7 | $149 |
| Ethicon US, LLC | 1 | $113 |
| Ardelyx, Inc. | 5 | $107 |
Products named: REZDIFFRA, RINVOQ, XIFAXAN, DUPIXENT, SKYRIZI, TREMFYA, ENTYVIO, XELJANZ.
Industry payments across VA — which companies pay providers there.
